Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 9;22(1):429.
doi: 10.1186/s12876-022-02514-4.

Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study

Laicheng Wang #  1 , Dan Hu #  2 , Zongcheng Fan  1 , Jianjian Yu  1 , Shunpeng Zhang  1 , Yunchai Lin  1 , Xin Chen  1 , Xiandong Lin  3 , Xiyao Yan  4 , Jinxiu Lin  1 , Feng Peng  5
Affiliations

Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study

Laicheng Wang et al. BMC Gastroenterol. .

Abstract

Background: Gastric cancer is often comorbid with hypertension and diabetes mellitus and increases the mortality risk.

Materials and methods: We conducted this prospective cohort study to investigate antidiabetics and antihypertensives' impact on gastric cancer survival. 3012 patients with gastric carcinoma undergoing radical gastrectomy were enrolled since January 2000 and followed up until July 2020.

Results: Hypertension and diabetes patients had worse survival than patients without hypertension and diabetes [median survival time (MST): 48 versus 112.5 months, p < 0.001 for hypertension, MST: 32.7 versus 183+ months, p < 0.001 for diabetes]. Compared to untreated patients, treated patients had better survival (MST: 109.7 months versus 39.1 months, p < 0.001 for antihypertensives, MST: 120.9 months versus 22.3 months, p < 0.001 for antidiabetics). Antihypertensives and antidiabetics were related to 42% (HR 0.58, 95% CI 0.47-0.73, p < 0.001) and 70% (HR 0.30, 95% CI 0.24-0.38, p < 0.001) reduced mortality risk relative to those without medications. metformin and Calcium channel blockers can better-improved prognosis compared to others (p = 0.00029 and p = 0.015).

Conclusion: Post-surgical gastric cancer patients could benefit substantially from anti-diabetes and antihypertensive therapy. Metformin and Calcium channel blockers may be superior to other medications.

Keywords: Diabetes mellitus; FIESTA study; Gastric cancer; Hypertension; Mortality; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors have none conflict of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier survival curves per hypertension (the upper left panel) and diabetes mellitus (the lower left panel), antihypertension medication (the upper right panel), and antidiabetic medication (the lower right panel). HT, hypertension; DM, diabetes mellitus;
Fig. 2
Fig. 2
Overall and stratified analyses of effect with antihypertension therapy on mortality risk of post-surgical gastric cancer
Fig. 3
Fig. 3
Overall and stratified analyses of effect with antidiabetic therapy on mortality risk of post-surgical gastric cancer
Fig. 4
Fig. 4
Kaplan–Meier survival curves per antihypertension medication (the upper panel) and antidiabetic mellitus medication. CCB, calcium channel blockers; Others, patients undertaken other medication; Unclear, not knowledge of medication type
See this image and copyright information in PMC

References

    1. Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38. - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi: 10.3322/caac.21338. - DOI - PubMed
    1. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114. doi: 10.1161/CIRCULATIONAHA.115.020406. - DOI - PMC - PubMed
    1. Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOncol. 2021;3(1):48–58. doi: 10.1016/j.jaccao.2020.12.003. - DOI - PMC - PubMed